Date: 2015-01-22
Type of information: Milestone
Compound: new medicines targeting G-protein coupled receptors (GPCRs)
Company: AstraZeneca (UK) Heptares Therapeutics (UK)
Therapeutic area: CNS diseases - Cardiovascular diseases - Metabolic diseases - Inflammatory diseases
Type agreement: R&D
Action mechanism:
Disease: CNS diseases - Cardiovascular diseases - Metabolic diseases - Inflammatory diseases
Details: * On May 31, 2011, AstraZeneca and Heptares Therapeutics have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors (GPCRs). This collaboration brings together Heptares’ GPCR discovery expertise and proprietary technologies, including its StaR® technology, which engineers stabilized receptors allowing GPCRs to be investigated, with AstraZeneca’s biopharmaceutical discovery, development and commercial capabilities. Research conducted under the collaboration will focus on a number of specific GPCR targets linked to central nervous system/pain, cardiovascular/metabolic and inflammatory disorders from projects in AstraZeneca’s small and large molecule portfolio, including projects from AstraZeneca’s biologics unit, MedImmune. This research will act as the starting point for drug discovery by producing the first-ever stabilized forms of GPCRs in their natural pharmacological conformation. As part of a joint discovery effort, Heptares and AstraZeneca will engage their respective discovery teams, compound libraries, and other discovery technologies for the purposes of initial screening and lead identification. Results will be combined into a common pool and the best leads will be further optimised collaboratively. AstraZeneca will then select pre-clinical, small and large molecule candidates and will be solely responsible for preclinical and clinical development.
Financial terms: Under the terms of the agreement, AstraZeneca has worldwide commercial rights to product candidates emerging from the collaboration. Heptares will receive an upfront $6.25 million cash payment fee plus committed research funding and also qualifies for significant future payments depending on delivery of agreed milestones. Heptares will also receive royalties on sales of all products discovered through the joint research.
Latest news: